Conflicting effects of antioxidant supplementation on cancer prevention or promotion is of great concern to healthy people and cancer patients. Despite recent studies about antioxidants accelerating the progression of lung cancer and melanoma, antioxidants may still play a role in cancer prevention. Both tumor and antioxidants types influence the actual efficacy. However, little is known about the impact of different types of antioxidants on primary hepatocellular carcinoma (HCC), including non-mitochondrial-and mitochondrial-targeted antioxidants. Utilizing mouse models of chemical hepatocarcinogenesis, we showed that administration of non-mitochondria-targeted antioxidants N-acetylcysteine (NAC) and the soluble vitamin E analog, Trolox, prevented tumorigenesis, whereas administration of mitochondria-targeted antioxidants SS-31 (the mitochondria-targeted peptide) and Mito-Q (a derivative of ubiquinone) facilitated tumorigenesis. RNA sequencing revealed that NAC and SS-31 caused very different changes in the oxidation-reduction state and DNA damage response. In diethylnitrosamine (DEN)-treated primary hepatocytes, NAC and Trolox alleviated DNA damage by activating ataxiatelangiectasia mutated (ATM)/ATM and Rad3-related (ATR) for DNA repair whereas SS-31 and Mito-Q aggravated damage by inactivating them. Interestingly, partial recovery of SS-31-scavengened mitochondrial reactive oxygen species (mtROS) could alleviate SS-31-aggravated DNA damage. Localization of ATM between mitochondria and nuclei was altered after NAC and SS-31 treatment. Furthermore, blockage of phospho-ATR (p-ATR) led to the recurrence of NAC-ameliorated DEN HCC. In contrast, reactivation of p-ATR blocked SS-31-promoted DEN HCC. Conclusion: These results demonstrate that the type of antioxidants plays a previously unappreciated role in hepatocarcinogenesis, and provide a mechanistic rationale for exploring the therapeutic use of antioxidants for liver cancer. (HEPATOLOGY 2018;67:623-635).
F or a long time, popular wisdom has held that antioxidants neutralize reactive oxygen species (ROS) to quench the damage of oxidative stress (1, 2) and thus diminish cancer risks. However, large, randomized, clinical trials and some biological studies have presented conflicting results that antioxidants actually increase cancer risks, indicating a controversial role of antioxidants in carcinogenesis. (3) (4) (5) Abbreviations: 8-OHdG, 8-hydroxydeoxyguanosine; AP, apurinic/apyrimidinic; ATM, ataxia-telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; BRCA1, breast cancer susceptibility 1; CYP, cytochrome P450; CYP4A, cytochrome P450, family 4, subfamily a; DEN, diethylnitrosamine; DDR, DNA damage response; DSBs, double-strand breaks; GO, Gene Ontology; HCC, hepatocellular carcinoma; MDA, malondialdehyde; mtROS, mitochondrial ROS; NAC, N-acetylcysteine; NRF2, nuclear factor erythroid 2-related factor 2; P53BP1, p53 binding protein 1; p-ATM, phosphor-ATM; p-ATR, phosphor-ATR; PBS, phosphate-buffered saline; p-CHK1/2, phosphor-checkpoint kinases 1 and 2; PCNA, proliferating cell nuclear antigen; p-ERK, phosphor-extracellular signal-regulated kinase; RNA-seq, RNA sequencing; RR, relative risk; ROS, reactive oxygen species.
Moreover, the effects of antioxidants on the tumorigenesis and progression of distinct cancer types seem divergent. (6) (7) (8) Even for epithelial tumors, effects of antioxidants on colorectal cancers seem quite different from that on the gastrointestinal cancers (3) : Supplementation of b-carotene, vitamin C, or vitamin E is beneficial for colorectal cancer prevention (relative risk [RR] , 0.84 [0.65-1.07]), but detrimental to gastrointestinal cancer prevention (RR, 1.20 [0.74-1.95]). In addition, epidemiological evidences show the favorable or unfavorable effects of a variety of antioxidant supplements, even on the same type of cancer. (3, 4) For example, selenomethionine is effective protection against esophageal squamous cell cancer (RR, 0.91 [0.84-0.99]) whereas vitamin A or vitamin E is harmful (RR, 1.16 [1.10-1.24] ). The type of antioxidants specifically determines the effective outcome of cancer prevention. Thus, both tumor and antioxidant types seem to influence the actual efficacy of cancer treatment. The controversial results possibly connect with the biphasic roles of ROS in tumorigenesis. An excessive load of ROS causes irreversible destruction on cellular structure, whereas a low level of ROS activates multiple signaling pathways to regulate normal cellular physiology (9) and even triggers the defense system to protect against cellular damage. (10, 11) The sources of ROS generation mainly include mitochondria, nicotinamide adenine dinucleotide phosphate oxidase, and endoplasmic reticulum stress. (12) All ROS are not produced equally, and compartmentalization and concentration gradients are extremely vital. Given that abolition of all cellular ROS by vigorous use of antioxidants may be harmful, the failure of many antioxidant-based therapies may be explained by their ineffectiveness of scavenging ROS at the site of generation. (13) In fact, mitochondrialtargeted antioxidants have been reported as more potent inhibitors of lung cancer cell proliferation than the untargeted antioxidants in the cytosol. (14, 15) However, the impact of such antioxidants on hepatocellular carcinoma (HCC) remains uncertain. HCC, which is a prevalent malignancy linked to chronic tissue injury, stress, and persistent inflammation (16) and thus represents a serious therapeutic challenge. Novel strategies for HCC therapy are clearly urgently needed. Despite the discordance of some clinical trials and reports regarding antioxidants in HCC prevention, no studies have yet attempted to differentiate the impact of mitochondria-and non-mitochondria-targeted antioxidants on HCC.
Materials and Methods

ANIMALS AND HCC TUMORIGENESIS MODEL
Wild-type mice were bought from Shanghai Model Organisms Center Inc with pure C57BL/B6 background. All mice were housed under a standard 12-hour light/dark cycle and fed a standard rodent chow diet in Shanghai Model Organisms Center. All procedures regarding animals were conducted in accord with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. Fifteen-day-old mice were injected by diethylnitrosamine (DEN; 25 mg/kg), and 10% CCl 4 in olive oil was intraperitoneally injected twice a week at the dosage of 5 uL/g when mice were 4 weeks old. SS-31 (r-2 00 , 6 00 -DEN-KF-NH2; ChinaPeptides Co.) were intraperitoneally injected thrice a week (12.5 mg/kg), and N-acetylcysteine (NAC; 1009005; Sigma-Aldrich, To define the effect of antioxidants on hepatocarcinogenesis, we administered the untargeted antioxidants, NAC and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), or the mitochondria-targeted ones, SS-31 (the mitochondria-targeted peptide) and Mito-Q (a derivative of ubiquinone), (7, 17) to 15-day-old male mice given DEN alone. A single DEN injection results in efficient HCC production after 36 weeks. Two weeks after injection of DEN, above antioxidants were given by drinking water, feed, or intraperitoneal injection to those mice. Strikingly, the number of detectable HCCs was 4-fold lower in NAC-treated groups than in nontreatment controls (Fig. 1A,B) . Trolox administration, a structurally unrelated untargeted antioxidant, also distinctly decreased HCC formation (Fig. 1A,B) . On the contrary, HCC load was 3-fold higher in SS-31 treatment groups than in controls (Fig. 1A,B) . Similarly, another mitochondrial-targeted antioxidant Mito-Q supplementation of the diet increased tumor loads (Fig.  1A,B) . Here, above antioxidant-mediated suppression of specific resource of ROS in primary hepatocytes was confirmed by the different redox-sensitive probes staining. Total ROS staining with CM-H2DCFDA (DCF) in hepatocytes could be reduced by those antioxidants (Fig. 1C) . Specifically, mitochondria-derived ROS staining with mitochondria-derived superoxide (Mito SOX), mitochondrial hydrogen peroxide (Mito PY1), or mitochondria-derived singlet oxygen (si DMA) in hepatocytes were exclusively lessened by SS-31 and Mito-Q, but unaffected by NAC and Trolox (Fig. 1C,D) . (18) Moreover, no apparent alteration of circulating liver enzyme, alanine transaminase, was observed under above antioxidant long-time treatment (Supporting Fig. S1A ), indicating little toxicity to the liver.
Because of long-term HCC induction by DENalone treatment, we combined DEN and CCl 4 to accelerate HCC occurrence at the 14th week. This model shares classic features of popular human HCC development and faithfully recapitulates the natural history of chronic damage, inflammation, and fibrosis. In this model, gradual increase of ROS and adaption of antioxidation also occurred during HCC formation (Supporting Fig. S1B-D) . Similar to the DEN-alone model, the conflicting results were also observed after two types of antioxidant administration (Fig. 1E-G) . However, on the base of Sirius Red staining, no difference of hepatic fibrosis was displayed in this process ( Fig. 1F ), indicating ineffectiveness of both antioxidants on liver fibrosis. Ki67 immunostaining results also confirmed their conflicting effects on HCC proliferation (Supporting Fig.  S1E ). Accordingly, cell-cycle regulators, including proliferating cell nuclear antigen (PCNA), cyclin D1, and p-ERK (phosphor-extracellular signal-regulated kinase), were also detected in above groups (Fig. 1H) , supporting their opposite impacts on HCC formation.
RNA SEQUENCING REVEALS THE DISTINCT FEATURES OF NON-MITOCHONDRIA-AND MITOCHONDRIA-TARGETED ANTIOXIDANTS INFLUENCING THE OXIDATION-REDUCTION PROCESS AND DNA DAMAGE RESPONSE
RNA sequencing (RNA-seq) of DEN plus CCl 4 models showed the transcriptional changes differently induced by two types of antioxidants (Supporting Fig.  S2A ). Gene Ontology (GO) enrichment analysis revealed the great difference in the oxidation-reduction process (Supporting Fig. S2A ). Among the top 10 of the rich gene set, oxidation-reduction process was the common divisor among control, NAC, and SS-31 groups ( Fig. 2A and Supporting Fig. S2B ), indicating the change of redox probably cause diverse HCC ending. Further analysis implied that monooxygenase activity accounted for oxidation-reduction process ( To rule out the interference of nonparenchymal cells, hepatocytes were isolated from DEN-treated mice, cultured with phosphate-buffered saline (PBS), NAC, or SS-31 ( Fig. 2C) , and then RNA-seq analysis was performed. Unexpectedly, ClueGO analysis showed a significant enrichment of DNA damage response signaling in the groups NAC versus control (Supporting Fig. S3A ,B) and SS-31 versus control (Supporting Fig. S3C,D) . Clustering analysis revealed that 1,448 genes differentially expressed in NAC relative to PBS are also differentially expressed in SS-31 relative to PBS (Fig. 2D) . Likewise, ClueGo analysis of these different genes significantly pointed to DNA damage response signaling (Fig. 2E,F) . DNA damage also relates to the monooxygenase, CYP, (19) (20) (21) (22) which was altered by antioxidants in vivo (Supporting Fig.  S2D-F) . Together, it strongly implied that both antioxidants influence DNA damage response.
MITOCHONDRIA-TARGETED ANTIOXIDANTS AGGRAVATE DEN-INDUCED DNA DAMAGE, WHEREAS NON-MITOCHONDRIA-TARGETED ANTIOXIDANTS COUNTER THIS EFFECT
Next, we focused on DNA damage in above groups. Here, immunostaining of a DNA damage marker, 8-hydroxydeoxyguanosine (8-OHdG), or an indication of DEN-induced lipid peroxidation, malondialdehyde (MDA), revealed that SS-31 aggravated DNA damage but NAC alleviated it (Fig. 3A and Supporting S4A). Assessment of apurinic/apyrimidinic (AP) sites formation in liver tissues or isolated hepatic mitochondria further confirmed their conflicting effect on DEN-induced DNA damage during hepatocarcinogenesis (Fig. 3B) . Consistently, similar results were detected in those DENtreated primary hepatocytes (Supporting Fig. S4B ).
Our unexpected discovery of mitochondria-targeted antioxidants promoting DEN-induced hepatocyte DNA damage seems to contradict previous reports of high oxidative stress promoting DNA damage. (23) To access the effect of mitochondrial ROS (mtROS) on DEN-induced DNA damage, we recovered SS-31-scavenged ROS by addition of rotenone or antimycin, two inhibitors of the respiratory chain, to specifically prompt superoxide production in mitochondrion. (24) (25) (26) To minimize the harm to mitochondria in hepatocytes, 1 lM of rotenone or 10 lg/mL of antimycin was finally confirmed as a proper dose to recover the mtROS to the level before SS-31 treatment (Supporting Fig. S4C ). The data of confocal imaging of 8-OHdG nuclear staining intensity and AP sites formation revealed that SS-31-aggravated DNA damage was alleviated by rotenone or antimycin (Fig. 3C,D) , indicating the involvement of mtROS in the effect of SS-31 on HCC.
DNA damage response (DDR) is intimately linked with cancer because damage to DNA causes cancer and endows an intrinsic barrier against cancer development. Accordingly, DDR comprises DNA damage recognition, signal transduction, cell-cycle regulation, and DNA repair to attenuate DNA damage. (27, 28) The histone protein, H 2 AX, p53 binding protein 1 (P53BP1), and breast cancer susceptibility 1 (BRCA1) are key components in DNA damage response. (29) (30) (31) However, administration of NAC or Trolox increased their expressions in the nucleus, whereas SS-31 or Mito-Q reduced them (Fig. 3E) , inconsistent with the effects of both antioxidants on DEN-induced DNA damage. Intriguingly, increased apoptosis, measured by expressions of cleaved caspase-3 and poly(ADPribose) polymerase, was also observed only in NAC-or Trolox-treated groups (Supporting Fig. S4D,E) . It means that, in spite of strong DNA damage response, the non-mitochondrial-targeted antioxidants presumably improve DNA damage repair whereas some remaining unrepaired cells experienced apoptosis, which ultimately limited HCC 
(D) Detection of the formation of AP sites of hepatocytes from (C). (E)
Immunoblotting analysis of BRCA1, p53BP1, and p-H2AX in the nucleus and cytoplasm from liver tissues lysates. GADPH was used as a cytoplasmic loading control and histone 3 as nuclear control. Abbreviations: bp, base pairs; DAPI, 4 0 ,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; N.S., not significant. growth. Conversely, the mitochondria-targeted antioxidants most probably weakened DNA repair, leading to accumulation of gene mutations, genomic instability, and subsequently accelerating HCC initiation.
MITOCHONDRIA-TARGETED ANTIOXIDANTS DEACTIVATED DNA DAMAGE CHECKPOINT PROTEINS, WHEREAS NON-MITOCHONDRIA-TARGETED ANTIOXIDANTS ACTIVATE THEM
DEN-induced HCC model correlates with DNA double-strand breaks (DSBs). DSBs activate the ataxia telangiectasia mutated (ATM)-and/or ataxia telangiectasia and Rad3-related (ATR)-orchestrated DDR network to provide an inducible barrier that constrains tumor progression at the early stages by inducing senescence or cell death. (32) We next explored the phoshorylations of ATM and ATR in response to above antioxidants. Actually, NAC and Trolox markedly augmented the amounts of both phosphor-ATM (p-ATM) and phosphor-ATR (p-ATR) in liver lysates from the DEN-CCl 4 mouse model (Fig. 4A) . In addition, phosphor-checkpoint kinases (p-CHK) 1 and p-CHK2, the key downstream checkpoint substrates of ATM and ATR, are also up-regulated by NAC and Trolox (Fig. 4A) . Nevertheless, SS31 and Mito-Q inhibited their expressions (Fig. 4A) . Similar results were also observed in DEN-treated hepatocytes (Fig. 4B) . Thus, it is very likely that the different effects of both antioxidants on ATM/ATR activation cause the resultant difference of DNA repair and eventual DNA damage.
ATM is predominantly a nuclear protein. The observation that antioxidants affect ATM activity and DNA damage suggested that localized ROS signaling might directly influence ATM activation. Given that ATM localized in mitochondrial to modulate mitochondrial homeostasis, (33) we next examine whether antioxidants affect the translocation of ATM in cells. Indeed, a fraction of p-ATM protein was detected to increase in mitochondria, but decrease in nuclei, after SS-31 treatment (Fig. 4C,D) . By contrast, NAC treatment led to increased nuclear fraction of p-ATM (Fig.  4C,D) . Moreover, a confocal image of DEN-treated hepatocyte showed that NAC caused more ATM nuclear localization whereas SS-31 triggered more ATM mitochondrial localization (Fig. 4E) . Together, our study implied that interruption of ROS at the different position of production might activate distinct DNA damage response.
BLOCKAGE OF ATR LED TO THE RECURRENCE OF NAC-TREATED DEN HCC, WHEREAS REACTIVATION OF ATR BLOCKED SS-31-PROMOTED DEN HCC
To clarify whether alteration of ATM/ATR by antioxidants is involved in DNA damage and hepatocarcinogenesis, their small molecule inhibitor compounds were used in vitro and in vivo. In our study, the ATR inhibitor, VE-822, treatment reinforced DENinduced DNA damage, but this reinforcement was counteracted by NAC ( Fig. 5A-C) . In contrast, the ATR/ATM activator, chloroquine phosphate, partially alleviated DNA damage, but this alleviation was offset by SS-31 ( Fig. 5A-C) . The effects of NAC combined with VE-822, or SS-31 combined with chloroquine on p-ATR expression, further denoted the involvement of ATR in antioxidant-altered hepatocyte DNA repair (Fig. 5A) . Similarly, the ATM inhibitor, KU-60019, handling led to reversion of NAC-weakened DNA damage (Supporting S6A,B). Because of ATM as an upstream of ATR (34) and the similarly in inhibitory effects of ATM and ATR inhibitors on NACalleviated DNA damage in DEN-damaged hepatocytes, the ATR inhibitor, VE-822, and the ATR/ ATM activator, chloroquine phosphate, were subsequently applied in vivo. As expectedly, VE-822 treatment led to recurrence of NAC-lessened HCC, whereas chloroquine alleviated HCC and this alleviation could be countered by SS-31 ( Fig.  5D,E) . Together, it strongly suggested that nonmitochondria-and mitochondria-targeted antioxidants play the contradictory roles in hepatocarcinogenesis by inversely modulating ATM/ATR to involve in DNA damage repair.
Discussion
Our study reveals an inconsistent effect of nonmitochondria-and mitochondria-targeted antioxidants on hepatocarcinogenesis. In response to DEN-induced DNA damage, non-mitochondria-targeted antioxidants NAC and Trolox improve DNA damage repair to block hepatocarcinogenesis, whereas mitochondriatargeted antioxidants SS-31 and Mito-Q weaken DNA repair and accelerate hepatocarcinogenesis. One potential explanation for this contradictory impact on HCC is that mitochondrial-and non-mitochondrialderived ROS play different roles in HCC initiation. Accordingly, the imbalance of ROS inside of mitochondrion might promote genotoxin-induced DNA damage and subsequent carcinogenesis. The use of antioxidants in cancer prevention is still controversial. Recent studies about antioxidant vitamin E presented discordant results in cancer prevention. (3, 4, 7, 35) The major reason for discordance may be related to the complicated backgrounds of oxidative stress in different tumors. Mice studies showed that antioxidants are detrimental in protecting against lung and prostate cancer. (3, 5, 7, 36) However, earlier lung cancer preventive trials presented bcarotene supplements with a higher risk of lung cancer than vitamin E alone. (3) Different antioxidants seem to not exactly equal. One simple explanation for this difference is the different target sites of the antioxidants. In the current study, the conflicting effects of non-mitochondria-and mitochondria-targeted antioxidants on HCC indicate localized ROS as a signaling molecule to influence DNA repair. A sustained rise ROS can cause intracellular damage, (23) but persistent decrease of ROS by antioxidants promotes tumor progression. (3, 4, 7) One limitation of our study is that a lack of ROS inducers outside of mitochondria the effect of purely mitochondria-derived ROS on DNA damage by addition of rotenone or antimycin. Because of the strong toxicity, low doses of two drugs were used only in vitro, but attenuated SS-31-aggravated DNA damage (Fig. 3C,D) . The data suggest that scavenging ROS at the site of generation might distinctly influence the efficacy of particular interventions. This reasoning is consistent with previous studies that mtROS is required for the extension of worm life span, (37) but also contributes to cancer progression under certain circumstances. (38, 39) Together, our data suggest that homeostasis of ROS inside of mitochondrion protects against genotoxin-induced DNA damage and hepatocarcinogenesis. Therefore, it seems essential to distinguish the target site of antioxidants before their practical application.
Our data showed that antioxidants affect ATM/ ATR activation involved in DDR and DNA repair. DDR functions as a double-edged sword in cancer prevention. An efficient DNA damage repair system ensures genomic stability to prevent tumorigenesis, whereas unrepaired DNA damage causes apoptosis, unchecked proliferation, and carcinogenesis. (32) Although the precise mechanism of both antioxidants affecting ATM/ATR expression is unclear, we speculate that because a fraction of ATM protein can be activated by mitochondrial dysfunction to localize in mitochondria, (33) mitochondria-targeted antioxidants may affect the localization of ATM in mitochondria. Interestingly, our data showed that addition of SS-31 increased a fraction of p-ATM in mitochondria, but decreased that in nuclei, whereas NAC enhanced nuclear levels of p-ATM. One potential explanation is that the redox state inside or outside of mitochondria influences the activation or function of nuclear ATM. However, we cannot rule out the possibility of additional factors involved in changing the cellular localization of ATM. Another intriguing finding of NAC reducing both phosphor-and total p53 levels in liver tumors and cultured hepatocytes (Supporting Fig.  S5A ) does not support a direct role for p53 in regulating DNA repair in spite of p53 as a downstream regulator of phosphor-ATM. It remains to be determined how both antioxidants activate or inactivate ATM/ ATR and the DNA repair process.
Our results seem to contradict a recent report of NAC accelerating tumor metastasis. (40, 41) A reasonable explanation is our use of the carcinogen-induced hepatocarcinogenesis model to study the impact of antioxidants on tumor initiation or prevention, which is entirely distinct from models utlizing the oncogenes, B-Raf or K-Ras to reflect antioxidants on tumor progression. Given the rare occurrence of BRaf or K-Ras mutation in HCC, it seems reasonable for the conflicting impact of antioxidants on HCC and lung cancer. (42, 43) Our data showed that expressions of nuclear factor erythroid 2-related factor 2 (NRF2) and its target genes were down-regulated by NAC but up-regulated by SS-31 (Supporting Fig.  S5B ), to a certain extent, in accord with the latest study of NRF2 activation by antioxidants accelerating HCC metastasis. (44) It implied that different targeted antioxidants profoundly influence NRF2 in HCC initiation. Certainly, the possibility of additional factors involved in this process needs to be further studied. Thus, accurate differentiation of the roles of antioxidants in different tumors will account for diverse results.
Intriguingly, our current study presented a concurrence of alleviated genotoxin DEN-induced DNA lesions, but increased expression of damage signal protein p-H 2 AX in NAC and Trolox-treated groups (Fig. 3E) . The types of oxidative stress inducer and the time of administration of antioxidants possibly account for these different results. NAC is capable of quenching H 2 O 2 -induced DNA damage and repressing the expression of p-H 2 AX at the time of simultaneous addition of NAC and H 2 O 2 in cells. (45) However, in our DEN-induced HCC model, DNA damage mainly arises from the single DEN injection, and the following administration of antioxidants affected the DDR and DNA repair process despite elevated expression p-H 2 AX. Consumption of butylated hydroxyanisolecontaining diet before DEN challenge, a kind of antioxidant, could directly decrease instantaneous ROS from DEN injection and thereby reduce damaged DNA and HCC lesions. (46) In our model, application of antioxidants after DEN injection 2 weeks later considerably lowered the possibility of antioxidants directly neutralizing instant ROS from DEN injection. Combined with the results of NAC/Trolox promoting the expressions of p-ATM/p-ATR, and their downstream signaling p-H2AX, BRCA1, and P53BP1, (47, 48) the alleviation of DNA damage by NAC/Trolox is very possibly attributed to the improved repair. H 2 AX has multiple roles during DNA repair and apoptosis. (30, 45, 49) Given coexistence of ameliorated DNA damage and increased apoptosis in NAC-treated liver tissues, p-H2AX is assumed to make a strong response to activated ATM/ATR to be involved in the damaged DNA repair process. This assumption is consistent with the previous report that H 2 AX becomes rapidly phosphorylated to form p-H2AX and accumulates at sites of DNA damage with P53BP1 and BRCA1 to facilitate DNA repair. (30) Additional evidence is required to establish if H 2 AX serves as a mediator of cell apoptosis to mediate the death of those cells containing unrepaired DNA after NAC treatment.
We wonder whether the results would be the same in mice with HCC triggered by hepatitis viruses or oncogenes, rather than a chemical carcinogen DENinduced HCC. In a previous study, vitamin E was protective against c-myc and transforming growth factor alpha-induced HCC formation and increased chromosomal and mitochondrial DNA stability in the liver, (41, 50) which is, at least partially, consistent with our data. Another limitation of the study is that the precise clinical applicability of our findings remains unclear. Vitamin E intake has been reported to be inversely associated with liver cancer risk, whereas vitamin C and multivitamin use have a higher risk of liver cancer. (35) Further analyses and trials are essential and warranted to further extend and advance the current evidence.
